HRP20251339T1 - Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba - Google Patents

Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba

Info

Publication number
HRP20251339T1
HRP20251339T1 HRP20251339TT HRP20251339T HRP20251339T1 HR P20251339 T1 HRP20251339 T1 HR P20251339T1 HR P20251339T T HRP20251339T T HR P20251339TT HR P20251339 T HRP20251339 T HR P20251339T HR P20251339 T1 HRP20251339 T1 HR P20251339T1
Authority
HR
Croatia
Prior art keywords
compound
pyrrolo
amino
propylsulfonating
reagent
Prior art date
Application number
HRP20251339TT
Other languages
English (en)
Croatian (hr)
Inventor
Kapildev Kashmirilal ARORA
Jacob Cole DEFOREST
Andrew Kevern Hills
Brian Patrick Jones
Kris Nicole Jones
Chad Arthur LEWIS
Anil Mahadeo RANE
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20251339T1 publication Critical patent/HRP20251339T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HRP20251339TT 2018-07-06 2019-07-03 Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba HRP20251339T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694698P 2018-07-06 2018-07-06
US201862776642P 2018-12-07 2018-12-07
US201962855071P 2019-05-31 2019-05-31
EP19766356.0A EP3817810B1 (en) 2018-07-06 2019-07-03 Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
PCT/IB2019/055683 WO2020008391A1 (en) 2018-07-06 2019-07-03 Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof

Publications (1)

Publication Number Publication Date
HRP20251339T1 true HRP20251339T1 (hr) 2025-12-19

Family

ID=67928862

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251339TT HRP20251339T1 (hr) 2018-07-06 2019-07-03 Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba

Country Status (15)

Country Link
US (3) US10815240B2 (enExample)
EP (1) EP3817810B1 (enExample)
JP (1) JP7437646B2 (enExample)
KR (1) KR102568464B1 (enExample)
CN (1) CN112384282B (enExample)
AU (1) AU2019299666B2 (enExample)
BR (1) BR112020025701A2 (enExample)
CA (1) CA3105161C (enExample)
ES (1) ES3045115T3 (enExample)
HR (1) HRP20251339T1 (enExample)
IL (1) IL279926B2 (enExample)
MX (2) MX2020013896A (enExample)
TW (1) TWI709562B (enExample)
WO (1) WO2020008391A1 (enExample)
ZA (1) ZA202100196B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232470A1 (en) 2019-05-13 2020-11-19 Boragen, Inc. Chemical compounds
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
CN112279785B (zh) * 2020-10-29 2022-08-16 苏利制药科技江阴有限公司 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法
CN113583992B (zh) * 2021-07-15 2023-06-27 华东理工大学 一种还原胺化酶及其在仲胺合成中的应用
CN117980293A (zh) * 2021-09-10 2024-05-03 上海海和药物研究开发股份有限公司 具有enpp1抑制活性的异羟基肟酸类化合物及其用途
ES2993658B2 (es) 2023-06-27 2025-07-02 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
ES3040374A1 (es) * 2024-04-30 2025-10-30 Moehs Iberica Sl Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP4126781B2 (ja) 1998-10-26 2008-07-30 宇部興産株式会社 １−スルホニルピラゾール誘導体及びその製造方法
JP2003005323A (ja) 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CN102471248B (zh) 2009-08-10 2015-01-07 Bhi有限合伙公司 用于递送1,3-丙二磺酸的方法、化合物和组合物
US9006456B2 (en) 2011-07-08 2015-04-14 Syngenta Participations Ag Processes for the preparation of thietanamine
MA38347A1 (fr) 2013-02-22 2017-10-31 Pfizer Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体

Also Published As

Publication number Publication date
AU2019299666A1 (en) 2021-01-07
IL279926B1 (en) 2023-08-01
JP2020007308A (ja) 2020-01-16
CA3105161A1 (en) 2020-01-09
CN112384282A (zh) 2021-02-19
ES3045115T3 (en) 2025-11-27
IL279926B2 (en) 2023-12-01
EP3817810B1 (en) 2025-09-17
US20220127274A1 (en) 2022-04-28
CN112384282B (zh) 2024-07-02
KR102568464B1 (ko) 2023-08-21
TW202017929A (zh) 2020-05-16
US12018031B2 (en) 2024-06-25
US10815240B2 (en) 2020-10-27
BR112020025701A2 (pt) 2021-03-16
IL279926A (en) 2021-03-01
MX2020013896A (es) 2021-03-09
US20210009601A1 (en) 2021-01-14
US20200123159A1 (en) 2020-04-23
US11254684B2 (en) 2022-02-22
EP3817810C0 (en) 2025-09-17
EP3817810A1 (en) 2021-05-12
KR20210029234A (ko) 2021-03-15
CA3105161C (en) 2022-11-15
AU2019299666B2 (en) 2024-07-11
JP7437646B2 (ja) 2024-02-26
MX2023006842A (es) 2023-06-22
ZA202100196B (en) 2022-09-28
TWI709562B (zh) 2020-11-11
WO2020008391A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
HRP20251339T1 (hr) Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba
ES2728247T3 (es) Método para la preparación cíclica de taurina a partir de una sal de metal alcalino de ácido hidroxietil sulfónico y una sal de metal alcalino de ácido vinil sulfónico
CL2021000611A1 (es) Proceso para preparar n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida por acoplamiento entre un indazol y una pirimidina; ciclación para formar un azabenzimidazol y desprotección del grupo indazol con tfa puro (divisional de la solicitud no. 201803423)
UA80298C2 (en) 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
RU2016151208A (ru) Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
JP2015536296A5 (enExample)
JP2017504576A5 (enExample)
JP2020007308A5 (enExample)
HRP20201984T1 (hr) Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
HUE031416T2 (en) Preparation of 2- (5-Bromo-4- (4-cyclopropylnaphthalen-1-hydrazine) -4H-1,2,4-triazole-3-hydrazine) acetic acid \ t
JP2013049690A5 (enExample)
CN107001289A (zh) N‑酰基‑(3‑取代的)‑(8‑取代的)‑5,6‑二氢‑[1,2,4]三唑并[4,3‑a]吡嗪的新手性合成
HRP20130950T1 (hr) Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina
CA2401834A1 (en) Novel imidazotriazinones and the use thereof
GB1008463A (en) Dipyridylium salts
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
PL416323A1 (pl) 3,6-dichloro-2-metoksybenzoesan alkilobetainianu metylu, sposób jego otrzymywania oraz zastosowanie jako herbicyd
FI3873894T3 (fi) Bcl-2-inhibiittorin uusi suola, siihen liittyvä kidemuoto, menetelmä sen valmistamiseksi ja sitä sisältäviä farmaseuttisia koostumuksia
ES2523346T3 (es) Un proceso para preparar sal de tricloroaminoplatinato y los productos obtenidos en el mismo
JP2008543805A5 (enExample)
CL2021000302A1 (es) Proceso para la preparación de estimuladores de guanilato ciclasa soluble. (divisional de solicitud 202002283).
JP2013057908A5 (enExample)
US3393253A (en) Ureidophosphonates and preparation thereof
HRP20100217T1 (hr) POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA
BR112019009759A2 (pt) 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-hidróxi-3-(5-mercapto-1h-1,2,4-triazol-1-il)propil)piridin-3-il)óxi)benzonitrila e processos de preparação